Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access will find a wealth of contextualized life science insight ready to be viewed in the FENIX Marketplace.
Welcome to FENIX Syndicated Services. If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.
$599
Posted in: GLP-1RA, Glucose Monitoring, Other, Topics Sep 17 | 2025EASD 2025 Key Press Releases (September 16) Purchase Blast$599
Posted in: Basal Insulin, Dual/triple agonist, GLP-1RA, GLP-1RA + Basal, Other, Topics Sep 15 | 2025EASD 2025 Key Press Releases (September 15) Purchase Blast
$599
Posted in: Autologous, GLP-1RA, Other, Topics Sep 12 | 2025MIRA Acquires SKNY for CB1 Asset; Structure Initiates Ph2 Body Composition StudyPurchase Blast
$599
Posted in: Dual/triple agonist, Other, Topics Sep 10 | 2025Novo Restructures with Workforce Cuts; Lilly Registers New Tirzepatide and Retatrutide Ph3 MASLD Study; Tzield Approved in ChinaPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Sep 09 | 2025Lilly Partners for Obesity Gene Therapies and Small Molecule Drug Discovery; Novartis Acquires ASCVD Drug; Ascletis Ph1b Obesity Results Purchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Other, SGLT2i, Topics Sep 08 | 2025FDA and EMA Implement Anti-Compounding Measures; Novo and Novonesis Partner for Gut Microbiome Research; Lexicon Submits Additional Sota T1DM Data; Lingo Sponsors US Open Coverage; Hansoh Initiates Ph3 T2DM Program of Olatorepatide in ChinaPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Sep 05 | 2025Lilly Initiates Muvalaplin CVOT; Vivani Plans Ph1 Sema Implant Study; WHO Adds GLP-1RAs to Essential Medicines ListPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics Sep 04 | 2025Senseonics Loses Another Partner; Skye Hosts KOL Event and Shares DIO Data; Lilly Initiates New Ph1 Trial of Obesity Asset and Ph3 Orforglipron Trial in OA; MBX Doses First Patient with MBX 4291 Purchase Blast
$599
Posted in: GLP-1RA, Other, Topics Sep 03 | 2025NewSelf Gains FDA Approval for Weight Loss Program; Merck Oral PCSK9i and Vericiguat Data; Argo and Novartis Expand CV Partnership; Novartis Ph4 Leqvio Results; Biophytis Receives EMA Authorization; Gan & Lee H2H Ph3 Trial vs. WegovyPurchase Blast
$599
Posted in: Autologous, Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics Sep 02 | 2025ESC 2025: Novo, Roche/Alnylam, and AstraZeneca Present New Data; Medtronic Closes in on Abbott CGM Launch; Ionis Topline Ph3 Olezarsen Results; NMPA Accepts Hengrui’s Obesity Application; Ypsomed’s SmartPilot Receives 510(k) Clearance; Biophytis Ph2 BIO101 Obesity Study; Skye Completes Ph2 Nimacimab Dosing Purchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Other, Topics Sep 02 | 2025Lilly Terminates Two Naperiglipron Studies; Lingo Advertisement on Reddit; Serena Williams Becomes Ro Ambassador; Another Novo Executive Steps Down; Esperion Embraces EU Recommendations for Bempedoic Acid; Daiichi Unveils Development of Fixed-Triple Combination Tablet for Lowering LDL-CPurchase Blast
$599
Posted in: GLP-1RA, Other, Topics Aug 29 | 2025Teva's Generic Saxenda Approved by FDA; Dexcom Layoffs; FDA Accepts Proposal for MASH Surrogate Endpoint; Novo Partners with Replicate for srRNA R&D; Amylyx Prioritizes its GLP-1 Antagonist Development; Lilly Pauses Mounjaro Supply and Offers Discounts in UKPurchase Blast
$599
Posted in: Glucagon, Other, Topics Aug 27 | 2025Novo Adds Additional Partners to NovoCare; American Regent Announces Gvoke VialDx Launch Purchase Blast
$599
Posted in: GLP-1RA, Topics Aug 26 | 2025Lilly’s Ph3 ATTAIN-2 Results Set the Stage for Obesity Global Regulatory Filings Purchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics Aug 25 | 2025MannKind Acquires scPharmaceuticals; Amgen Olpasiran Primary Prevention Study; Repatha Label Expansion; Signos Launches OTC Weight Loss Platform with Dexcom’s Stelo; Roche Initiates New Ph1 Muscle Composition Study Purchase Blast
$599
Posted in: Dual/triple agonist, Other, Topics Aug 21 | 2025Gubra Q2 ‘25 Earnings; Advances New Obesity AssetPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Aug 21 | 2025Obesity Spotlight: Is Amgen's QM MariTide Dosing Enough?Purchase Blast
$599
Posted in: GLP-1RA, Other, SGLT2i, Topics Aug 20 | 2025Novo’s Hiring Freeze; UK Advocates for SGLT2is for Treatment of T2DMPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics Aug 20 | 2025Viking’s Topline AE Data Scares the Street; Medtronic Q2 ‘25 Earnings; Novo Partners for Oral Peptide Research; Rezdiffra Gains EU Marketing Authorization; UK Approves Tzield; Luna Closes Series A Funding Round; Health Canada Approves FLOW; EMA Accepts NewAmsterdam’s Obicetrapib MAA Purchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Aug 18 | 2025Wegovy MASH Label Analysis; Ozempic Offered Through NovoCarePurchase Blast